{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:58:36Z","timestamp":1792159116710,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the effectiveness and safety of changes to a protocol for refractory bleeding after cardiothoracic surgery. The protocol changes included adjusting from a weight-based to a fixed-dosing strategy for 4-factor prothrombin complex concentrate (4F-PCC) and decreasing the weight-based dosing of recombinant activated factor VII (rFVIIa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a pre-post retrospective cohort study evaluating 198 adult patients after cardiothoracic surgery requiring cardiopulmonary bypass at an academic medical center between May 2019 to October 2021 (before protocol change) and November 2021 to September 2022 (after protocol change). The primary outcome was chest tube output at 24\u2005hours after the operation in patients who received at least one dose of 4F-PCC or rFVIIa. Secondary endpoints included transfusion volume, the rate of re-exploration events, length of stay, and 30-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary outcome of chest tube output at 24\u2005hours was 720\u2005mL in the pre-change group and 700\u2005mL in the post-change group (P = 0.982). The volume of fresh frozen plasma (FFP) transfusions significantly decreased from a median of 4 units to 2 units (P &amp;lt; 0.001). The median dose of 4F-PCC in the pre- vs post-change group was 24.6 vs 26.3 units\/kg (P = 0.011), while that of rFVIIa was 59.5 vs 24.5\u2005\u03bcg\/kg (P &amp;lt; 0.001). The other secondary and safety outcomes were similar between the groups. The average cost savings was $3,585.45 per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients in the post-change group had similar chest tube output, re-exploration rates, and incidence of thrombotic events. The post-change group received significantly less FFP and less coagulation factor concentrate while maintaining hemostasis and reducing cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag339","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:24:28Z","timestamp":1791804268000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of coagulation factor concentrates for persistent bleeding after cardiothoracic surgery"],"prefix":"10.1093","author":[{"given":"Maria F","family":"Hartwig","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Loyola University Medical Center , Maywood, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-9825","authenticated-orcid":false,"given":"RaeAnn","family":"Hirschy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Loyola University Medical Center , Maywood, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Meckel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Loyola University Medical Center , Maywood, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026101609371426600_zxag339-B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1749-8090-2-17","article-title":"Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study","volume":"2","author":"Jimenez Rivera","year":"2007","journal-title":"J Cardiothorac Surg"},{"issue":"1","key":"2026101609371426600_zxag339-B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13054-015-1172-6","article-title":"Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery","volume":"20","author":"Cappabianca","year":"2015","journal-title":"Crit Care"},{"issue":"9","key":"2026101609371426600_zxag339-B3","doi-asserted-by":"publisher","first-page":"e0162396","DOI":"10.1371\/journal.pone.0162396","article-title":"Active bleeding after cardiac surgery: a prospective observational multicenter study","volume":"11","author":"Colson","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"2026101609371426600_zxag339-B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13019-021-01473-3","article-title":"Bleeding risk stratification in coronary artery surgery: the should-not-bleed score","volume":"16","author":"Petricevic","year":"2021","journal-title":"J Cardiothorac Surg"},{"issue":"3","key":"2026101609371426600_zxag339-B5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/icvts\/ivs224","article-title":"Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery","volume":"15","author":"Arn\u00e9kian","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"4","key":"2026101609371426600_zxag339-B6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.athoracsur.2018.10.013","article-title":"Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis","volume":"107","author":"Roman","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"2026101609371426600_zxag339-B7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1060028017752365","article-title":"Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery","volume":"52","author":"Mehringer","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"19","key":"2026101609371426600_zxag339-B8","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101609371426600_zxag339-B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.108.834275","article-title":"Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery","volume":"120","author":"Gill","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"2026101609371426600_zxag339-B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/icvts\/ivy067","article-title":"Recombinant activated factor VII is associated with postoperative thromboembolic adverse events in bleeding after coronary surgery","volume":"27","author":"Habib","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"4","key":"2026101609371426600_zxag339-B11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jtcvs.2018.03.167","article-title":"A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: lessons from an observational study","volume":"156","author":"Hoffmann","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"2026101609371426600_zxag339-B12","doi-asserted-by":"publisher","first-page":"e213936","DOI":"10.1001\/jamanetworkopen.2021.3936","article-title":"Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial","volume":"4","author":"Karkouti","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2026101609371426600_zxag339-B13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/anae.15327","article-title":"Prothrombin complex concentrate vs fresh frozen plasma in adult patients undergoing heart surgery\u2014a pilot randomised controlled trial (PROPHESY trial)","volume":"76","author":"Green","year":"2021","journal-title":"Anaesthesia"},{"issue":"5","key":"2026101609371426600_zxag339-B14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1213\/ANE.0000000000004355","article-title":"Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients","volume":"129","author":"Raphael","year":"2019","journal-title":"Anesth Analg"},{"issue":"2","key":"2026101609371426600_zxag339-B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/ject-2100053","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"53","author":"Tibi","year":"2021","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"2026101609371426600_zxag339-B16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/anae.15181","article-title":"A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients","volume":"76","author":"Erdoes","year":"2021","journal-title":"Anaesthesia"},{"issue":"4","key":"2026101609371426600_zxag339-B17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/vox.12774","article-title":"Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis","volume":"114","author":"Hashmi","year":"2019","journal-title":"Vox Sang"},{"issue":"2","key":"2026101609371426600_zxag339-B18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/0885066620984443","article-title":"A comparison of prothrombin complex concentrate and recombinant activated factor VII for the management of bleeding with cardiac surgery","volume":"37","author":"Katz","year":"2022","journal-title":"J Intensive Care Med"},{"issue":"20","key":"2026101609371426600_zxag339-B19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2019.17312","article-title":"Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial","volume":"322","author":"Callum","year":"2019","journal-title":"JAMA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag339\/71915107\/zxag339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag339\/71915107\/zxag339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:37:20Z","timestamp":1792157840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag339\/8914576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag339","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"article-number":"zxag339"}}